Sigyn Therapeutics Inc

Addressing Life-Threatening Inflammatory Conditions Precipitated by Cytokine Storm Syndrome

[Sigyn Therapeutics Inc @Sigyn_inc]

Health care-associated infections are one of the most frequent adverse events in care delivery settings. These infections are often resistant to antibiotics and can rapidly lead to #sepsis. Novel therapies are needed, and #Sigyn Therapeutics has a new approach to treat sepsis.

[Sigyn Therapeutics Inc @Sigyn_inc]

In case you missed it! Jeremy Ferrell, CPA, MBA was recently appointed as Chief Financial Officer of #Sigyn Therapeutics. He brings over 25 years of finance and operations leadership experience to our company.
Learn more: https://t.co/gXYPbmYoti

[Sigyn Therapeutics Inc @Sigyn_inc]

Did you know that regional disparities in sepsis incidence and mortality exist? 85% of sepsis cases and deaths worldwide occur in low- and middle-income countries. We believe that #sigyn extracorporeal system will increase access to innovative therapies around the world.

[Sigyn Therapeutics Inc @Sigyn_inc]

We're thrilled to announce Alexander S. Yevzlin, M.D., FASN has joined our Scientific Advisory Board. He's a recognized leader in the field of Interventional Nephrology & has been involved in the development of multiple medical devices. $SIGY Learn more:
https://t.co/MaNWk9mjbr

[Sigyn Therapeutics Inc @Sigyn_inc]

Please join us in welcoming H. David Humes, M.D., to our Scientific Advisory Board. Dr. Humes is a world-renowned scholar in the areas of nephrology, acute renal failure, biomaterials, medical devices, and extracorporeal therapy. $SIGY
https://t.co/hWIIZuld5t

[Sigyn Therapeutics Inc @Sigyn_inc]

Did you know that #cytokinestorm is a life-threatening condition involving elevated levels of circulating cytokines that can be triggered by various therapies, infections, cancers and autoimmune conditions? At #Sigyn we are creating novel therapeutic modalities for this condition

[Sigyn Therapeutics Inc @Sigyn_inc]

We welcome Ajay Verma, M.D., Ph.D. to our Scientific Advisory Board. He's a recognized thought leader in the field of neurology and drug development, and brings decades of pharmaceutical industry experience to our team. $SIGY
Learn more: https://t.co/vcyqj6uNWN

[Sigyn Therapeutics Inc @Sigyn_inc]

In his CEO Notes, our CEO Jim Joyce provides comprehensive information regarding the development of our lead asset, Sigyn Therapy, which has broad-spectrum potential to help treat inflammatory conditions. $SIGY

Learn more from our suite of #CEONotes:
https://t.co/Z34Fs187wd

[Sigyn Therapeutics Inc @Sigyn_inc]

What is #SigynTherapy?

We are developing Sigyn Therapy as a broad-spectrum solution to life-threatening inflammatory conditions with limited treatment options. $SIGY

Learn more:
https://t.co/Emla7BpHel

[Sigyn Therapeutics Inc @Sigyn_inc]

Our mission is to develop novel technologies that use blood purification to save patients’ lives. We're working to the bridge the gap of current therapeutic options through our broad-spectrum technology, #Sigyn Therapy.
Learn more:
https://t.co/wKoWUwFfxO

[Sigyn Therapeutics Inc @Sigyn_inc]

Interested in learning more about our work and upcoming presentations and events? Check out the #NewsAndEvents section of our website for the latest and greatest!

https://t.co/ZjJhU99Obh

[Sigyn Therapeutics Inc @Sigyn_inc]

In a recent ep. of @Finding_genius, our CEO Jim Joyce explains the potential benefits of a broad-spectrum blood purification device to treat life-threatening conditions. $SIGY

#TuneIn here:
https://t.co/fiYFh2QTBN

[Sigyn Therapeutics Inc @Sigyn_inc]

Improving #patientsafety starts with pursuing better patient outcomes.

Learn more about #PatientSafetyAwarenessWeek from @ASHRM:
https://t.co/xYKRCMcFVX

[Sigyn Therapeutics Inc @Sigyn_inc]

#ICYMI: In a recent article from @Biospace, our CEO Jim Joyce covered how #blood detoxification technology like #SigynTherapy can fight antibiotic-resistant microorganisms known as #superbugs. $SIGY

Read more:
https://t.co/JqvkfEByv2

[Sigyn Therapeutics Inc @Sigyn_inc]

As we progress further into 2022, we are excited to continue sharing updates on #SigynTherapy as it progresses through clinical development. #StayTuned! $SIGY

In the meantime, read more about our work:
https://t.co/wKoWUwFfxO

[Sigyn Therapeutics Inc @Sigyn_inc]

It’s #RareDiseaseDay!

Through our ongoing clinical development, we hope to address a broad-spectrum of issues, including rare conditions like #Hepatic Encephalopathy (#HE).

Learn more about supporting patients with rare conditions:
https://t.co/UBwRJuTunY

[Sigyn Therapeutics Inc @Sigyn_inc]

Cytokine Storm Syndrome underlies many deadly diseases that currently do not have significant therapeutic options.

Through our work with #SigynTherapy and #bloodpurification tech, we hope to bring a new lifesaving option to patients. $SIGY

Learn more:
https://t.co/Ra0vHVOBlk

[Sigyn Therapeutics Inc @Sigyn_inc]

Sepsis continues to be a severe issue for ill patients; our goal is to address this condition and increase positive outcomes for those affected by #sepsis. #SIGY

Learn more about #SigynTherapy:
https://t.co/Emla7BpHel

[Sigyn Therapeutics Inc @Sigyn_inc]

The outbreak of #COVID19 has shifted perspectives regarding therapeutic developments; it is time to consider whether broad-spectrum responses are timelier than overly complicated targeted therapies.

Read more from $SIGY CEO Jim Joyce in @MedDeviceNews1:
https://t.co/yPqRqFwF8N

[Sigyn Therapeutics Inc @Sigyn_inc]

Sigyn Therapy is designed to address a broad spectrum of inflammatory targets, including #sepsis, by removing #cytokines and pathogenic markers from the bloodstream. $SIGY

Learn more about #SigynTherapy’s potential range:
https://t.co/CjJJDApD78